CA3244038A1 - COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT - Google Patents

COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT

Info

Publication number
CA3244038A1
CA3244038A1 CA3244038A CA3244038A CA3244038A1 CA 3244038 A1 CA3244038 A1 CA 3244038A1 CA 3244038 A CA3244038 A CA 3244038A CA 3244038 A CA3244038 A CA 3244038A CA 3244038 A1 CA3244038 A1 CA 3244038A1
Authority
CA
Canada
Prior art keywords
inhibitor
cyclopropanesulfonamido
ctps1
thiazol
bcl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3244038A
Other languages
English (en)
French (fr)
Inventor
Philip BEER
David CHIRON
Andrew Parker
Catherine PELLAT-DECEUNYNCK
Original Assignee
Step Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Step Pharma SAS filed Critical Step Pharma SAS
Publication of CA3244038A1 publication Critical patent/CA3244038A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3244038A 2022-03-01 2023-03-01 COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT Pending CA3244038A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22305225.9 2022-03-01
EP22305225 2022-03-01
EP22306429.6 2022-09-27
EP22306429 2022-09-27
PCT/EP2023/055217 WO2023166076A1 (en) 2022-03-01 2023-03-01 Combinations of ctps1 and bcl2 inhibitors for cancer

Publications (1)

Publication Number Publication Date
CA3244038A1 true CA3244038A1 (en) 2023-09-07

Family

ID=85384465

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3244038A Pending CA3244038A1 (en) 2022-03-01 2023-03-01 COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT

Country Status (6)

Country Link
US (1) US20250177394A1 (https=)
EP (1) EP4486347A1 (https=)
JP (1) JP2025508896A (https=)
AU (1) AU2023228045A1 (https=)
CA (1) CA3244038A1 (https=)
WO (1) WO2023166076A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
WO2024133730A1 (en) * 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717465B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
MX2020009887A (es) 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
EP3980410B1 (en) 2019-06-04 2025-02-19 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP4041715A1 (en) 2019-09-20 2022-08-17 Step Pharma S.A.S. Sulfonamide inhibitors as ctps 1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4486347A1 (en) 2025-01-08
AU2023228045A1 (en) 2024-08-15
US20250177394A1 (en) 2025-06-05
JP2025508896A (ja) 2025-04-10
WO2023166076A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
CA3244038A1 (en) COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT
WO2023166078A1 (en) Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
JP6356919B2 (ja) Ｈｉｖの処置のためのイソキノリン化合物
TWI651303B (zh) 經取代苯化合物
WO2023166077A1 (en) Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2024133721A1 (en) Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
JP2022124458A (ja) 新規メチルキナゾリノン誘導体
KR20150093695A (ko) Malt1의 소분자 억제제
WO2023166080A1 (en) Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
EP4637770A1 (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2013148114A1 (en) P300/cbp inhibitors and methods of use
JP2013533276A (ja) タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
EP4041725B1 (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade
JP2018510134A (ja) 組合せがん治療法
JP2024533121A (ja) 混合系統キナーゼ阻害薬および使用方法
JP2023539754A (ja) Ｌｚｋ標的化分解剤および使用方法
US10428105B2 (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
CN118804752A (zh) Ctps1和bcl2抑制剂联合治疗癌症
WO2026027753A1 (en) Ctps1 inhibitors for the treatment of myeloproliferative neoplasms
CN111615391B (zh) 比卡格韦的代谢物
He Unraveling PI5P4K’s Immunomodulatory Role in Lung Cancer Tumor Microenvironment⎯ A Druggable Target to Promote Anti-Tumor Immunity
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase as potential anti-cancer drugs: A patent review (2002-2014)
KR20240164498A (ko) 이중 lsd1/hdac 억제제
JP2024064068A (ja) ウイルス増殖阻害剤

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240812

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240813

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240813

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241125

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241125

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224